Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RAS oncogene protein refers to a family of small GTPases (HRAS, KRAS, and NRAS) that act as molecular switches in numerous cellular signaling pathways. Mutations in these genes are among the most common genetic alterations found in human cancers, leading to constitutive activation of RAS and driving uncontrolled cell growth, proliferation, and survival. RAS regulates multiple key pathways including Raf-MEK-ERK and PI3K-AKT. It has long been considered a challenging target, but recent advances have begun exploring direct targeting strategies.
Direct RAS inhibition, inhibition of downstream signaling pathways (e.g., MEK inhibition)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAS Oncogene Protein (RAS).